United States - English - NLM (National Library of Medicine)

calvin, scott and company, incorporated - phendimetrazine tartrate (unii: 6985ip0t80) (phendimetrazine - unii:ab2794w8kv) - phendimetrazine tartrate tablets are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. the limited usefulness of agents of this class (see clinical pharmacology ) should be measured against possible risk factors inherent in their use such as those described below. known hypersensitivity or idiosyncratic reactions to sympathomimetics. advanced arteriosclerosis, symptomatic cardiovascular disease, moderate and severe hypertension, hyperthyroidism and glaucoma. highly nervous or agitated patients. patients with a history of drug abuse. patients taking other cns stimulants, including monoamine oxidase inhibitors. phendimetrazine tartrate tablets are defined by the drug enforcement administration as a schedule iii controlled substance. phendimetrazine tartrate is related chemically and pharmacologically to the amphetamines. amphetamines and related stimulant drugs have been extensively abused and the possibility of

United States - English - NLM (National Library of Medicine)

calvin, scott and company, incorporated - diethylpropion hydrochloride (unii: 19v2pl39ng) (diethylpropion - unii:q94yyu22b8) - diethylpropion hydrochloride extended release tablets, 75 mg are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (bmi) of 30 kg/m2 or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. below is a chart of bmi based on various heights and weights. bmi is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. metric conversions are as follows: pounds divided by 2.2 = kg; inches x 0.0254 = meters. body mass index (bmi), kg/m2 weight (pounds) height (feet, inches) 5’0” 5’3” 5’6” 5’9” 6’0” 6’3” 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 th

United States - English - NLM (National Library of Medicine)

calvin, scott and company, incorporated - phendimetrazine tartrate (unii: 6985ip0t80) (phendimetrazine - unii:ab2794w8kv) - phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (bmi) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. below is a chart of body mass index (bmi) based on various heights and weights. bmi is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters body mass index (bmi), kg/m2 height (feet, inches) the usefulness of agents of this class (see clinical pharmacology ) should be measured against possible risk factors inherent in their use such as those described below.

United States - English - NLM (National Library of Medicine)

calvin scott & co., inc. - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine is indicated for the treatment of: - acute and maintenance treatment of major depressive disorder [see clinical studies (14.1)] . - acute and maintenance treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd) [see clinical studies (14.2)] . - acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe bulimia nervosa [see clinical studies (14.3)] . - acute treatment of panic disorder, with or without agoraphobia [see clinical studies (14.4)] . fluoxetine and olanzapine in combination is indicated for the treatment of: - acute treatment of depressive episodes associated with bipolar i disorder. - treatment resistant depression (major depressive disorder in pat

India - English - Central Drugs Standard Control Organization

alde medi. - eye dps - 10ml

India - English - Central Drugs Standard Control Organization

zydus cadila - elemental calcium,vit.d3 - tab - 250mg,125iu - 10

India - English - Central Drugs Standard Control Organization

zydus cadila - elemental calcium,vit.d3 - tab - 500mg,250iu. - 10

India - English - Central Drugs Standard Control Organization

zydus cadila - cal.gluconolactobionate,vit.b12,vit.d3 - inj - 137.5mg,50mcg,5000iu. - 15ml v.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - calcium carbornate -

Philippines - English - FDA (Food And Drug Administration)

biopharm chemicals co., ltd.; importer: cathay drug co., inc.; distributor: cathay drug co., inc. - cholecalciferol (vitamin d3), minerals - film coated tablet - each film-coated tablet contains: cholecalciferol (vitamin d1) calcium (equivalent to 1500 mg calcium carbonate) magnesium (equivalent to 66.31 mg magnesium oxide) zinc (equivalent to 9.34 mg zinc oxide) 200 iu 600 mg 40 mg 7.5 mg manganese (equivalent to 5.54 mg manganese sulfate) copper (equivalent to 1.25 mg copper oxide) boron (equivalent to 2.2 mg sodium borate) 1.8 mg i mg 250 mcg